# Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.

> **NIH NIH R44** · TORRALVA MEDICAL THERAPEUTICS, LLC · 2024 · $522,934

## Abstract

PROJECT SUMMARY:
According to the Centers for Disease Control (CDC), synthetic opioids are currently the most common cause of
overdose death in the U.S., and have increased opioid deaths by >500% from 2015- 2020. In 2020 alone, over 80% of the
69,700 opioid deaths were attributed to these synthetics (fentanyl). Despite the widespread availability of naloxone, the
only FDA approved treatment for opioid overdose, deaths from fentanyl and fentanyl analogues (F/FA) continue to rise in
parallel with increasing reports and pharmacological evidence of F/FA resistance to naloxone. High doses of rapidly
injected F/FA cause airway obstruction from vocal cord closure (VCC) and severe chest wall rigidity (CWR) within 60-90
seconds, lethal effects that can persist for up to 10 minutes and appear to be resistant to naloxone. In contrast, morphine
derived opiates (e.g. heroin) cause respiratory depression and mild muscle rigidity that is responsive to naloxone, but are
not known to cause VCC in humans. The rapidly lethal phenomenon of VCC suggests unique pharmacological
mechanisms underlying F/FA effects and may be a factor driving the dramatic increase in community overdose deaths. In
support of this hypothesis, our published pharmacological data demonstrate F/FA, but not morphine or naloxone, have
affinity for off-site targets that regulate these F/FA-induced effects. These in vitro data include F/FA concentrations that
may be physiologically relevant to humans, based on available models of brain lipid concentrations for F/FA and by
comparison with plasma levels in decedents of fentanyl overdose. Additionally, we have demonstrated in our published
animal model that intravenous fentanyl induces VCC in <10 seconds, is not reversed by high dose naloxone and involves
these off-site receptor targets. These data suggest that the development of effective therapies for overdose requires a
biological model that replicates clinical effects of F/FA toxicity and a re-conceptualization of the underlying causes of
F/FA overdose deaths to include VCC, in addition to respiratory depression. Therefore, the goal of this Fast-track
proposal is to use an animal model of fentanyl toxicity, to identify specific drug classes that address F/FA induced VCC
and respiratory depression. There are currently no Federal Drug Administration approved treatments that target these
F/FA toxicity effects, and this project directly addresses the need for the development of a new class of therapeutics,
specific to F/FA overdose.

## Key facts

- **NIH application ID:** 11021257
- **Project number:** 4R44DA056267-02
- **Recipient organization:** TORRALVA MEDICAL THERAPEUTICS, LLC
- **Principal Investigator:** Phillip Randolph Torralva
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $522,934
- **Award type:** 4N
- **Project period:** 2022-09-15 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11021257

## Citation

> US National Institutes of Health, RePORTER application 11021257, Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model. (4R44DA056267-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11021257. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*